Last 22 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -2.55 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 25.96 | 15.15 | 105.38 | 27.64 | 36.13 | 125.89 | 17.85 | 31.53 | 43.61 | 54.10 | 40.58 | 34.15 | 26.33 |
| — | -88.0% | +490.4% | -12.3% | -17.2% | +132.7% | -56.0% | -7.7% | +65.6% | +106.7% | +14.8% | -25.4% | -54.3% | |
| P/B Ratio | 1.45 | 1.90 | 2.08 | 2.30 | 2.28 | 2.20 | 3.55 | 3.11 | 5.87 | 4.96 | 3.74 | 3.21 | 2.97 |
| — | -13.2% | -41.3% | -26.1% | -61.1% | -55.7% | -5.2% | -3.1% | +97.4% | +68.3% | -21.3% | +0.1% | +20.0% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Recursion Pharmaceuticals, Inc.'s operating margin was -304.8% in Q4 2025, up 3022.7 pp QoQ and up 3768.9 pp YoY. The trailing four-quarter average of -1463.2% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 113.3% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 5.0% | 24.4% | -471.8% | -5.5% | -48.0% | -183.6% | 53.7% | 36.1% | 17.2% | 7.0% | -7.7% | 14.8% | -2.6% |
| — | +113.3% | -978.9% | -115.3% | -378.8% | -2725.5% | +799.8% | +143.6% | +766.0% | -66.3% | +57.5% | +117.3% | +94.5% | |
| Operating Margin | -867.9% | -304.8% | -3327.6% | -922.5% | -1297.9% | -4073.8% | -377.1% | -698.0% | -714.1% | -931.2% | -985.4% | -741.8% | -575.8% |
| — | +92.5% | -782.4% | -32.2% | -81.7% | -337.5% | +61.7% | +5.9% | -24.0% | -108.8% | -105.6% | +14.2% | +45.5% | |
| Net Margin | -863.4% | -304.2% | -3135.3% | -899.8% | -1373.3% | -3966.0% | -366.8% | -677.2% | -677.3% | -875.3% | -920.8% | -696.5% | -538.4% |
| — | +92.3% | -754.7% | -32.9% | -102.8% | -353.1% | +60.2% | +2.8% | -25.8% | -108.2% | -98.8% | +18.7% | +49.0% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -59.5% | -9.9% | -16.5% | -18.6% | -20.6% | -22.9% | -17.3% | -19.8% | -21.1% | -20.6% | -20.5% | -17.1% | -14.3% |
| — | +56.7% | +4.3% | +6.3% | +2.7% | -11.2% | +15.9% | -16.0% | -48.2% | -56.8% | -40.1% | -21.2% | -32.1% | |
| ROA | -44.1% | -7.5% | -12.0% | -13.2% | -14.7% | -16.5% | -12.7% | -14.6% | -15.1% | -14.5% | -14.3% | -11.9% | -9.8% |
| — | +54.3% | +5.7% | +9.9% | +2.5% | -13.6% | +11.2% | -23.3% | -53.4% | -65.3% | -52.3% | -27.2% | -18.1% | |
| ROIC | -95.8% | -17.4% | -27.2% | -26.3% | -26.7% | -37.4% | -38.1% | -42.8% | -52.5% | -66.1% | -68.5% | -97.2% | — |
| — | +53.6% | +28.5% | +38.5% | +49.2% | +43.3% | +44.4% | +56.0% | — | — | +83.2% | +26.4% | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has improved 44.4% YoY to 5.50x, strengthening the short-term liquidity position. Debt/Equity has declined for 6 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.07 | 0.07 | 0.08 | 0.10 | 0.10 | 0.10 | 0.17 | 0.15 | 0.13 | 0.11 | 0.12 | 0.11 | 0.12 |
| — | -34.2% | -54.5% | -37.7% | -21.7% | -4.1% | +47.0% | +36.3% | +3.0% | +4.1% | -12.6% | -8.1% | +16.8% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.50 | 5.50 | 4.60 | 3.58 | 4.11 | 3.81 | 4.35 | 6.07 | 4.65 | 4.70 | 4.36 | 3.78 | 5.34 |
| — | +44.4% | +5.7% | -41.0% | -11.5% | -19.0% | -0.2% | +60.4% | -13.0% | -17.3% | -24.8% | -33.0% | -26.1% | |
| Quick Ratio | 5.50 | 5.50 | 4.60 | 3.58 | 4.11 | 3.81 | 4.35 | 6.07 | 4.65 | 4.70 | 4.36 | 3.78 | 5.34 |
| — | +44.4% | +5.7% | -41.0% | -11.5% | -19.0% | -0.2% | +60.4% | -13.0% | -17.3% | -24.8% | -33.0% | -26.1% | |
| Interest Coverage | -358.08 | — | -206.73 | -367.14 | — | -303.75 | -177.86 | -255.19 | -4817.00 | -3805.00 | -3982.00 | -3142.88 | -3677.11 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 22 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonRecursion Pharmaceuticals, Inc.'s current P/E is -2.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Recursion Pharmaceuticals, Inc.'s current operating margin is -867.9%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Recursion Pharmaceuticals, Inc.'s business trajectory between earnings reports.